Go To Global Site
Welcome to UCB in the United States

Jun

29

We are Stronger When We Respond to COVID-19 Together

At UCB, we know we’re stronger when we work together. Read more from Patty Fritz, VP of U.S. Corporate Affairs, about how UCB adapted in response to the COVID-19 pandemic to met the new unique needs of the patients, caregivers, health care providers, and health systems we’re committed to serving.

Jun

25

Living with Myasthenia Gravis - Jennifer's Story

For MG Awareness Month, we're spreading awareness about myasthenia gravis (MG) by showcasing Jennifer's inspiring story about living with the disease. Hear about her experience and advice for others living with MG by watching the video below.

Jun

24

UCB Announces New Data from its Epilepsy Portfolio Presented on the American Academy of Neurology Virtual Platform

Six poster presentations highlight clinical data on NAYZILAM® (midazolam) nasal spray CIV and BRIVIACT® (brivaracetam) CV in addition to epilepsy-related health economics outcomes research


Atlanta, Ga., June 24, 2020: UCB today announced six posters selected for presentation at the 72nd American Academy of Neurology (AAN) annual meeting, available online via the 2020 AAN Science Highlights virtual platform, which replaced the in-person event previously cancelled due to the COVID-19 pandemic. The abstracts were also published in the online supplement to Neurology.

Jun

22

Celebrating MG Awareness Month, Together From Afar

Although this June may look and feel different from years past, we’re just as excited to spread awareness together with the myasthenia gravis (MG) community in celebration of Myasthenia Gravis (MG) Awareness Month. In light of the impact coronavirus is having on people around the world, especially people with MG who may be immunocompromised, we’re looking forward to connecting and celebrating in a virtual way.

Jun

19

UCB Statement on Racism and Racial Injustice

Over the last several weeks, UCB has shared deep concern and sadness about the state of racial injustice and heinous acts of violence against Black Americans happening in our country. We remain committed to living our Patient Value Principles to respect all people and to embrace diversity of thought, experience, and background. At UCB, we do not tolerate racism and racial injustice in any form.

Jun

17

Bringing Human Connection to Immunology Patients During COVID-19

UCB has been making ongoing adjustments to ensure continuous care for patients, including people living with immune-mediated inflammatory diseases during this time of great isolation. Hear more from UCB's Head of U.S. Immunology, Camille Lee, about our efforts to better support patients during this time.

Jun

12

Press Release: First Presentations of Bimekizumab Phase 3 Data Demonstrate Superior Skin Clearance Over Placebo and Stelara at Week 16 in Adults with Moderate-to-Severe Plaque Psoriasis

• Data from the Phase 3 BE VIVID and BE READY studies show that bimekizumab-treated patients with psoriasis achieved significant skin clearance at week 16, rapid response after one dose, and durability of response up to a year
• Results support the importance of selectively inhibiting IL-17F, in addition to IL-17A, with bimekizumab

Jun

11

Empowering Patients Impacted by Immuno-Dermatological Conditions

At UCB, everything we do starts with one simple question: “How will this make a difference in the lives of people living with severe diseases?” This question is our motivation, inspiration and what challenges us to stay focused on what will ultimately benefit the patients we serve. Read more from Camille Lee, Head of U.S. Immunology, about how UCB is working to empower patients impacted by immuno-dermatological conditions.

Jun

05

Press Release: UCB acquires Engage Therapeutics: Staccato Alprazolam - A potential solution for acute on-demand seizure management for people living with epilepsy

• Underlines UCB’s leadership in epilepsy by adding Staccato® Alprazolam, a drug-device-combination with the potential to be the first on-demand, single-use treatment to rapidly terminate an active epileptic seizure